donislecel-jujn

Trade name: Lantidra

Cell therapyapprovedOrphan Drug FDA

Approved

Jun 28, 2023

Clinical trial activity

0 trials · 0 clinical orgs · 1 marketing orgs

Phase 1
0
Phase 2
0
Phase 3
0
Phase 4
0

Timeline

2010s

  1. Feb 1, 2017

    Orphan Drug Designation

2020s

  1. Jun 28, 2023

    Celltrans — Earliest FDA Approval

  2. Jun 28, 2023

    Celltrans — NDA Organization

Indications

Mechanism of action

Approval history

  • approvedJun 28, 2023

Chemistry & pharmacology

Oral

No

Parenteral

No

Topical

No

Organizations

Marketing (1)

OrganizationOrg typeRelationshipDate
CelltransAcademic/HospitalNDAJun 28, 2023